Vanessa Pataia,  —

Renovion has raised $8.1 million in a financing round, supporting further development and planned clinical testing of ARINA-1, a nebulized treatment for chronic lung diseases like cystic fibrosis (CF) and non-CF bronchiectasis, and for lung transplants. “Patient and laboratory studies have…

Eloxx Pharmaceuticals has resumed enrollment in its Phase 2 clinical trial evaluating ELX-02 in cystic fibrosis (CF) patients in Israel and Europe, after it was temporarily halted due to the COVID-19 pandemic.  “We are pleased that enrollment in our Phase 2 clinical…

Pravibismane suspension, a new type of inhaled antimicrobial medication developed by Microbion, has received orphan drug designation from the U.S. Food and Drug Administration…

Different types of Staphylococcus aureus can be found persistently in the airways of cystic fibrosis (CF) patients, but this bacteria population is influenced by age and prior antibiotic treatment, a new study says. …

University students with cystic fibrosis (CF) are invited to apply to AbbVie’s CF Scholarship program and a chance to receive up to $25,000 for the upcoming school year. The program supports U.S. residents with CF…

Long-term treatment with Kalydeco (ivacaftor) in people with cystic fibrosis (CF) is associated with a better body mass index, lung function, and a lesser effort required to breath, a small study reports. The single-site study, “Long‐term…

Eloxx Pharmaceuticals has temporarily paused enrollment in Phase 2 clinical trials of ELX-02 in cystic fibrosis (CF) patients in response to the COVID-19 pandemic. According to Eloxx,…

The presence of heme B — a component of red blood cells — in the lungs is linked to worse lung function in people with cystic fibrosis (CF). That finding was described in the study “Refinement…

An imbalance in the microbes that populate the gut of infants with cystic fibrosis (CF) affects their growth throughout the first year of life. This finding was detailed in the study “Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure” published…

Arrevus announced that the U.S. Food and Drug Administration (FDA) has given a form of priority review to ARV-1801 (sodium fusidate tablets), a potential oral treatment of pulmonary exacerbations in people with cystic fibrosis (CF). A clinical trial in patients is in planning stages, the company added in a…